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Background
Inhaled corticosteroid (ICS)/long-acting b2-agonist
(LABA) therapies are the recommended maintenance
treatment option for adults with persistent asthma
(1). One such therapy is budesonide/formoterol in
one dry-powder inhaler (DPI) (Symbicort
  Turbu-
haler
 , AstraZeneca R&D, Lund, Sweden), a combi-
nation that has been shown in numerous trials to be
an effective and well-tolerated treatment for asthma
(2–7).
The pharmacological properties of budesonide/for-
moterol mean that this combination is suitable for
use in different settings. The formoterol component
is associated with a rapid onset of bronchodilatory
effect, similar to that of standard, short-acting
b2-agonist (SABA) reliever medications, such as salb-
utamol (8), as well as an extended duration of
action, which is comparable with that of salmeterol
(9). Budesonide, on the other hand, has a prolonged
dwell time in the airway tissues, resulting in a long
duration of anti-inﬂammatory effect (10–12). These
properties mean that budesonide/formoterol is effec-
tive when given once daily (2) and when used in the
acute setting (13). In addition, the nature of the
dose–response curves of both budesonide and formo-
terol (14–16) means that temporarily increasing the
dose of budesonide/formoterol in response to
decreasing asthma control can provide patients with
additional clinical beneﬁts without increasing the risk
of adverse systemic effects. As such, budesonide/
formoterol is uniquely suitable for adjustable
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SUMMARY
Background: Budesonide/formoterol is an effective treatment for both asthma
and chronic obstructive pulmonary disease. This study compared the efﬁcacy and
safety of a novel hydroﬂuoroalkane (HFA) pressurised metered-dose inhaler (pMDI)
formulation of budesonide/formoterol with that of budesonide pMDI and budeso-
nide/formoterol dry-powder inhaler (DPI; Turbuhaler
 ). Methods: This was a
12-week, multinational, randomised, double-blind, double-dummy study involving
patients aged ‡ 12 years with asthma. All patients had a forced expiratory volume
in 1 s of 50–90% predicted normal and were inadequately controlled on inhaled
corticosteroids (500–1600 lg/day) alone. Following a 2-week run-in, during which
they received their usual medication, patients were randomised (two inhalations
twice daily) to budesonide pMDI 200 lg, budesonide/formoterol DPI 160/4.5 lg
or budesonide/formoterol pMDI 160/4.5 lg. The primary efﬁcacy end-point was
change from baseline in morning peak expiratory ﬂow (PEF). Results: In total,
680 patients were randomised, of whom 668 were included in the primary analy-
sis. Therapeutically equivalent increases in morning PEF were observed with budes-
onide/formoterol pMDI (29.3 l/min) and budesonide/formoterol DPI (32.0 l/min)
(95% conﬁdence interval: )10.4 to 4.9; p ¼ 0.48). The increase in morning PEF
with budesonide/formoterol pMDI was signiﬁcantly higher than with budesonide
pMDI (+28.7 l/min; p < 0.001). Similar improvements with budesonide/formoterol
pMDI vs. budesonide pMDI were seen for all secondary efﬁcacy end-points. Both
combination treatments were similarly well tolerated. Conclusions: Budesonide/
formoterol, administered via the HFA pMDI or DPI, is an effective and well-toler-
ated treatment for adult and adolescent patients with asthma, with both devices
being therapeutically equivalent.
What’s known
The efﬁcacy and safety of budesonide/formoterol
administered via dry powder inhaler (DPI) are well
established. However, pressurised metered-dose
inhalers (pMDIs), the most commonly used inhala-
tion devices in many countries worldwide, are cur-
rently being developed with hydroﬂuoroalkane
(HFA)-based propellants to avoid the well-known
ozone-depleting effects of chloroﬂuorocarbon pro-
pellants. Accordingly, budesonide/formoterol has
also been reformulated as an HFA pMDI (Symbicort
Rapihaler
 ).
What’s new
The present study demonstrates that budesonide/
formoterol administered via the novel HFA pMDI is
an effective and well-tolerated treatment for adults
and adolescents, and is therapeutically equivalent
to budesonide/formoterol delivered via a DPI. These
data provide further understanding of the use of
the different budesonide/formoterol devices, and
ultimately, will help provide clinicians and patients
with greater freedom to select a delivery system
that meets their needs and preferences.
doi: 10.1111/j.1742-1241.2007.01574.x
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tenance and reliever therapy [Symbicort
  Mainte-
nance and Reliever Therapy (SMART)] (5–7,19).
Although the use of DPIs, such as Turbuhaler
 ,i s
well established, pressurised metered-dose inhalers
(pMDIs) are the most commonly used inhalation
devices in many countries worldwide (20). The
majority of available pMDI devices contain chloro-
ﬂuorocarbon (CFC) propellants, which have well-
documented adverse effects on the atmospheric
ozone layer. Over the past few years, research has led
to the development and approval of hydroﬂuoroal-
kane (HFA)-based aerosols – which do not have
ozone-depleting properties – as alternatives to CFC
propellants (21). Accordingly, budesonide/formoterol
has also been reformulated as an HFA pMDI (Sym-
bicort Rapihaler
 ) to provide clinicians and patients
with greater freedom to select a delivery system that
meets their needs and preferences.
The aim of this study was to compare the efﬁcacy
and safety of the new pMDI formulation of budeso-
nide/formoterol with that of budesonide/formoterol
DPI and budesonide (Pulmicort
 , AstraZeneca R&D,
Lund, Sweden) pMDI in adults and adolescents with
asthma.
Methods
Patients
Adult and adolescent outpatients (aged ‡ 12 years)
with asthma (22) for ‡ 6 months, who were inade-
quately controlled on ICS alone, were enrolled. For
inclusion, patients had to have a forced expiratory
volume in 1 s (FEV1) ‡ 50% and £ 90% of predicted
normal (prebronchodilator), reversibility of ‡ 12%
FEV1 after inhalation of terbutaline 1 mg (Bricanyl
 
Turbuhaler
 , AstraZeneca) and a history of daily ICS
use (stable dose of 500–1600 lg/day within 30 days
prior to enrolment) for ‡ 3 months.
Before randomisation, all patients had to have a
total asthma symptom score ‡ 1o n‡ 4 of the last
7 days of run-in (scale: 0 ¼ no symptoms, 1 ¼
aware of symptoms but can tolerate them easily,
2 ¼ asthma causing enough discomfort to interfere
with normal activities or sleep and 3 ¼ unable to
perform normal activities or sleep because of asthma;
day- and nighttime scores summed). The ﬁrst patient
was enrolled on 30th April 2002 and the last patient
completed the study on 6th February 2003.
Study design
This was a 12-week, phase III, randomised, double-
blind, double-dummy, parallel-group study con-
ducted in 62 centres across eight countries (Brazil,
Bulgaria, Canada, Hungary, Mexico, the Philippines,
Thailand and the UK). The study complied with
Good Clinical Practice guidelines and the ethical
principles of the Declaration of Helsinki. An inde-
pendent ethics committee or institutional review
board approved the study protocol and patient con-
sent form at each centre.
Patients were instructed to stop taking their LABA
therapy for 3 days prior to the beginning of the run-
in period (visit 1). Also, those using an ICS/LABA
combination were requested to stop treatment with
the combination 3 days before visit 1 and to con-
tinue with the same ICS alone. SABA use was
restricted at 6 h prior to visit 1. During the study
period [run-in and treatment period (visits 1–5)]
any b2-agonists other than study reliever and revers-
ibility test medication were not permitted.
Following a 10- to 14-day run-in, during which
patients continued their prestudy ICS medication
(stable dose), patients were randomised to treatment
(two inhalations twice daily) with one of the follow-
ing: budesonide pMDI 200 lg (Pulmicort
  pMDI);
budesonide/formoterol DPI 160/4.5 lg (Symbicort
 
Turbuhaler
 ); or budesonide/formoterol pMDI 160/
4.5 lg (Symbicort Rapihaler
 ). The doses of budeso-
nide in each group were comparable; differences are
explained by labelling changes for new inhaled drugs
that require the delivered dose to be reported rather
than the metered dose.
Patients were randomised sequentially in blocks of
six using a computer-generated randomisation sche-
dule. Eligible patients were consecutively allocated the
lowest available randomisation code. The treatment
code was only broken in the case of medical emergen-
cies. The randomisation schedule was computer gen-
erated at AstraZeneca Research and Development,
Charnwood, UK. To maintain blinding, each patient
also received a placebo device. To reduce inconve-
nience, each patient received only two of the three
devices: one active and one placebo device. An inhaled
SABA (terbutaline 0.5 mg per inhalation or equiva-
lent) was available for all patients for symptom relief.
Assessments
The primary efﬁcacy end-point was the change in
morning peak expiratory ﬂow (PEF) from baseline
(mean of the last 10 days of run-in) to the mean
value over the 12-week treatment period. Secondary
efﬁcacy end-points included: change from baseline
(mean of the last 10 days of run-in) to the mean
value over the treatment period in evening PEF;
reliever medication use; reliever medication-free days;
nighttime awakenings caused by asthma; asthma
symptom score; symptom-free days (a night and day
without asthma symptoms and no nighttime awaken-
ings caused by asthma); and asthma-control days (a
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medication use and no nighttime awakenings caused
by asthma). All PEF measurements [taken prior to
inhalation of study medication using a Mini-Wright
 
peak ﬂow meter (Clement Clarke, Harlow, UK)],
reliever medication use, nighttime awakenings caused
by asthma and asthma symptom scores were
recorded by patients in a daily diary.
Change from baseline (week 0) to the mean of
the treatment period (weeks 2–12) in FEV1 and
change from baseline (week 0) to the end of treat-
ment (week 12) in Asthma Quality of Life Ques-
tionnaire (standardised version) [AQLQ(S)] scores
(23) were also predeﬁned secondary end-points.
FEV1 was assessed during clinic visits at enrolment
and randomisation and at 2, 6 and 12 weeks
postrandomisation, according to European Respira-
tory Society recommendations (24,25). The 32-item
AQLQ(S) was administered during clinic visits at
randomisation and at weeks 2 and 12 (seven-point
scale: 1 ¼ greatest possible impairment and 7 ¼
least impairment) (23). A change in AQLQ(S) score
of ‡ 0.5 units was deﬁned as a clinically relevant
change (26).
Safety assessments included adverse events
(assessed throughout), vital signs (assessed at enrol-
ment, randomisation, weeks 2 and 12) and clinical
laboratory parameters (haematology, clinical chemis-
try and urinalysis; assessed at randomisation, weeks 2
and 12).
All patients received instruction on how to use the
pMDI and DPI devices and the peak ﬂow metre
before the start of the study at visit 1. Each partici-
pating study site was provided with a Turbuhaler/
pMDI to be used with disposable mouthpieces/actua-
tors, allowing patients to practise the inhalation tech-
nique.
Statistical analysis
The intent-to-treat (ITT) population (i.e. all rando-
mised patients with postrandomisation data) was
used for the main efﬁcacy analyses. The primary
objective of the study was to show that budeso-
nide/formoterol pMDI was more efﬁcacious than
budesonide pMDI. The study was powered on this
primary objective and approximately 600 evaluable
patients (200 in each arm) were required for a
90% probability of detecting a true difference
between budesonide/formoterol pMDI and budeso-
nide pMDI of 13 l/min in mean change in morn-
ing PEF, assuming a standard deviation of 40 l/
min (two-group t-test with a 5% two-sided signiﬁ-
cance level).
A secondary objective was to compare the efﬁ-
cacy of budesonide/formoterol pMDI with that of
budesonide/formoterol DPI. Therapeutic equivalence
between budesonide/formoterol pMDI and budeso-
nide/formoterol DPI was considered to be established
if the 95% conﬁdence interval (CI) for the mean
difference in morning PEF was within the prespeci-
ﬁed equivalence limits of )15 and +15 l/min, as
described previously (27). Assuming a standard
deviation of 40 l/min, there was 90% probability
of this CI being contained within these limits
given that the actual difference was < 1.5 l/min.
Results of the secondary analysis were not ad-
justed for multiplicity but a per-protocol (stability)
analysis (excluding patients who violated the
inclusion/exclusion or randomisation criteria) was
performed to conﬁrm the therapeutic equivalence
data.
Diary-card end-points, averaged over available
data, were analysed using a validated analysis of vari-
ance (ANOVA) model with treatment and country
as ﬁxed factors and the run-in mean (last 10 days) as
a covariate. FEV1 and AQLQ(S) were also analysed
using an ANOVA model with treatment and country
as ﬁxed factors and the randomisation value as a
covariate. Safety variables were analysed using
descriptive statistics.
Results
Patients
A total of 892 patients were enrolled and 680 were
subsequently randomised to study treatment (217 to
budesonide pMDI, 229 to budesonide/formoterol
DPI and 234 to budesonide/formoterol pMDI). The
ITT and safety populations comprised 679 patients
(one patient in the budesonide/formoterol pMDI
group was lost to follow-up). For the primary analy-
sis, 216, 223 and 229 patients in the budesonide
pMDI, budesonide/formoterol DPI and budesonide/
formoterol pMDI groups, respectively, had morning
PEF data from both the run-in and the treatment
period. Six hundred patients completed the study;
discontinuations were comparable between the three
treatment groups (29, 23 and 27 for budesonide
pMDI, budesonide/formoterol DPI and budesonide/
formoterol pMDI, respectively).
Patients’ demographics and baseline characteristics
were well balanced across the three treatment groups
(Table 1). In total, 109 (16%) patients were aged
12–17 years, 520 (76%) were aged 18–64 years and
51 (8%) were aged ‡ 65 years; the distribution of
adolescent and elderly patients was even across the
three groups. Self-reported adherence to study medi-
cation (percentage of diary-logged days on which
study medication was used) was equally high across
all the three treatment groups (> 98%).
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Budesonide/formoterol DPI and budesonide/formo-
terol pMDI improved morning PEF compared with
budesonide pMDI (p < 0.001 for both) (Figure 1).
Following treatment, the adjusted mean change in
morning PEF was 31.4 and 28.6 l/min higher in the
budesonide/formoterol DPI and budesonide/formo-
terol pMDI groups, respectively, than in the budeso-
nide pMDI group. Analysis of improvements from
baseline in morning PEF with budesonide/formoterol
DPI and budesonide/formoterol pMDI established
that the two treatments were therapeutically equiva-
lent (Table 2). A stability analysis of improvements
from baseline in morning PEF in the per-protocol
population conﬁrmed the therapeutic equivalence of
the two budesonide/formoterol inhalation devices;
the adjusted mean difference between budesonide/
formoterol pMDI and budesonide/formoterol DPI
was )4.9 l/min (95% CI: )12.8 to 3.0; p ¼ 0.22).
All secondary diary end-points were improved to a
greater extent with budesonide/formoterol DPI and
budesonide/formoterol pMDI than with budesonide
pMDI (Table 3; Figure 2). For most end-points, the
improvements seen with budesonide/formoterol
pMDI were similar to those observed with budeso-
nide/formoterol DPI, with the exception of symp-
tom-free and asthma-control days, which were
increased by a slightly greater degree with budeso-
Table 1 Patient demographics and baseline characteristics
Characteristic
Budesonide pMDI
(n = 217)
Budesonide/formoterol
DPI (n = 229)
Budesonide/formoterol
pMDI (n = 234)
Males/females, n 68/149 89/140 94/140
Mean age (range), years 40 (12–79) 39 (11–78)* 40 (12–78)
Smokers, n (%) 14 (6) 11 (5) 13 (6)
Median time since diagnosis (range), years 10 (0–70) 9 (1–63) 8 (1–58)
Mean morning PEF (range), l/min 318 (109–638) 321 (93–668) 326 (89–715)
Mean FEV1 (range)
% predicted 71 (45–91) 69 (50–90) 71 (39–92)
1 2.01 (0.85–4.25) 2.09 (1.05–3.75) 2.07 (0.94–4.12)
Mean ICS at entry (range), lg/day 759 (400–1600) 774 (500–1600) 776 (400–1600)
LABA use at entry, n (%) 32 (15) 33 (14) 30 (13)
Reliever medication use (range), inhalations/day 2.0 (0.0–14.5) 1.8 (0.0–11.3) 2.1 (0.0–11.4)
Reliever medication-free days (range), % 29 (0–100) 34 (0–100) 29 (0–100)
Total asthma symptom score (range), 0–6 2.1 (0.4–5.7) 2.0 (0.0–6.0) 1.9 (0.0–5.3)
Nights with awakenings (range), % 33.1 (0–100) 32.1 (0–100) 29.2 (0–100)
Symptom-free days (range), % 10 (0–80) 12 (0–100) 12 (0–100)
Asthma-control days (range), % 8 (0–80) 10 (0–89) 10 (0–100)
AQLQ(S) (range), 1–7 4.80 (1.8–6.8) 4.62 (1.8–7.0) 4.70 (1.4–7.0)
*One patient was 11 years and 354 days old at the enrolment visit. Deviations from inclusion criteria not considered sufﬁciently sig-
niﬁcant to justify exclusion of data from the full analysis. AQLQ(S), Asthma Quality of Life Questionnaire (standardised version); DPI,
dry-powder inhaler; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; PEF, peak expira-
tory ﬂow; pMDI, pressurised metered-dose inhaler.
Figure 1 Change in morning PEF following treatment with budesonide pMDI, budesonide/formoterol DPI or budesonide/
formoterol pMDI. DPI, dry-powder inhaler; NS, not signiﬁcant; PEF, peak expiratory ﬂow; pMDI, pressurised metered-
dose inhaler
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improvements in diary end-points, both budesonide/
formoterol DPI and budesonide/formoterol pMDI
also improved FEV1 compared with budesonide
pMDI (Figure 3), with no signiﬁcant difference
between the two budesonide/formoterol devices.
Health-related quality of life
Budesonide/formoterol DPI and budesonide/formo-
terol pMDI provided similar clinically relevant
improvements in health-related quality of life (Fig-
ure 4). These improvements with budesonide/formo-
terol DPI and budesonide/formoterol pMDI were
statistically greater than those provided by budeso-
nide pMDI [adjusted mean change in AQLQ(S)
overall score: +0.76 (p < 0.001 vs. budesonide
pMDI), +0.65 (p ¼ 0.002 vs. budesonide pMDI) and
+0.37, respectively]. For the overall AQLQ(S) score,
52% and 56% of budesonide/formoterol pMDI-trea-
ted and budesonide/formoterol DPI-treated patients,
respectively, had a clinically relevant increase of ‡ 0.5
units compared with 35% of patients in the budeso-
nide pMDI group.
Safety
There were no clinically important differences
between treatment groups with regard to adverse
events [overall (Table 4) and ICS- and b2-agonist-
related events (Table 5)], vital signs or laboratory
parameters. Only 32% of patients experienced one or
more adverse events, the majority of which were
mild or moderate in severity. Four patients reported
serious adverse events: two in the budesonide pMDI
group (joint dislocation/accident/fracture, asthma
aggravated) and two in the budesonide/formoterol
pMDI group (menorrhagia, increase in liver enzyme
activity); none were considered (after follow-up) to
be related to study treatment. No deaths were
reported.
Thirty patients (15 in the budesonide pMDI
group, four in the budesonide/formoterol DPI
group and 11 in the budesonide/formoterol pMDI
Table 2 Therapeutic equivalence of budesonide/formoterol DPI and budesonide/formoterol pMDI
Comparison
Morning PEF (l/min)
Adjusted mean
difference 95% CI p-value
Budesonide/formoterol pMDI vs. budesonide/formoterol DPI )2.8 )10.4 to 4.9* 0.48
Budesonide/formoterol pMDI vs. budesonide pMDI 28.6 20.9–36.4 < 0.001
Budesonide/formoterol DPI vs. budesonide pMDI 31.4 23.7–39.2 < 0.001
*Therapeutic equivalence was deﬁned as a 95% CI for the difference in morning PEF between budesonide/formoterol pMDI and budes-
onide/formoterol DPI within the range )15 to +15 l/min. CI, conﬁdence interval; DPI, dry-powder inhaler; PEF, peak expiratory ﬂow;
pMDI, pressurised metered-dose inhaler.
Table 3 Changes in secondary diary end-points following treatment with budesonide pMDI, budesonide/formoterol
DPI or budesonide/formoterol pMDI
Variable
Adjusted mean change from run-in
Budesonide
pMDI (n = 217)
Budesonide/formoterol
DPI (n = 229)
Budesonide/formoterol
pMDI (n = 233)
Evening PEF, l/min )0.6 25.1* 24.3*
Reliever medication use, no. of inhalations/24 h )0.35 )0.92* )0.94*
Reliever medication-free days, % 17.9 31.1* 30.8*
Total asthma symptom score, 0–6 )0.44 )0.84* )0.70*
Nights with awakenings, % )9.7 )15.5 )16.5*
Symptom-free days, % 19.1 34.2* 28.0
Asthma-control days, % 18.3 33.1* 26.5
*p < 0.001, p < 0.01 vs. budesonide pMDI; p < 0.05 budesonide/formoterol DPI vs. budesonide/formoterol pMDI. DPI, dry-powder
inhaler; PEF, peak expiratory ﬂow; pMDI, pressurised metered-dose inhaler.
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events. The most frequently reported adverse event
causing discontinuation was asthma aggravated
[seven, two and one patient(s) in the budesonide
pMDI, budesonide/formoterol DPI and budesonide/
formoterol pMDI groups, respectively]. Other
adverse events leading to discontinuation included
nausea, tremor, palpitations and lower respiratory
tract infection.
Discussion
Budesonide/formoterol, which is available as a DPI,
has been reformulated as an HFA pMDI to enable
delivery of this effective and well-tolerated therapy
via two different devices that meet the needs and
requirements of both patients and clinicians alike
without detriment to the environment. This large-
scale, international, double-blind, double-dummy
study set out to compare the efﬁcacy and safety of
this novel pMDI formulation of budesonide/formo-
terol with that of the established DPI, budesonide/
formoterol Turbuhaler
 , and budesonide pMDI in
adults and adolescents with inadequately controlled
asthma.
Analysis of the primary end-point – morning PEF
– demonstrated that both budesonide/formoterol
therapies are more effective than budesonide pMDI.
Figure 3 Change in FEV1 following treatment with
budesonide pMDI, budesonide/formoterol DPI or
budesonide/formoterol pMDI. DPI, dry-powder inhaler;
E, enrolment; FEV1, forced expiratory volume in 1 s;
pMDI, pressurised metered-dose inhaler; R, randomisation;
W, week
Figure 2 Change in (A) total asthma symptoms and (B) reliever medication-free days following treatment with budesonide
pMDI, budesonide/formoterol DPI or budesonide/formoterol pMDI. DPI, dry-powder inhaler; pMDI, pressurised
metered-dose inhaler
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Adverse event
No. of patients (%)*
Budesonide
pMDI (n = 217)
Budesonide/formoterol
DPI (n = 229)
Budesonide/formoterol
pMDI (n = 233)
Patients with ‡ 1 event 82 (38) 66 (29) 70 (30)
Nasopharyngitis 17 (8) 6 (3) 4 (2)
Upper respiratory tract infection 9 (4) 9 (4) 7 (3)
Pharyngitis 7 (3) 8 (3) 4 (2)
Lower respiratory tract infection 6 (3) 4 (2) 2 (1)
Headache 4 (2) 4 (2) 4 (2)
Inﬂuenza 5 (2) 2 (1) 4 (2)
Wheezing 5 (2) 3 (1) 2 (1)
Oral candidiasis 3 (1) 5 (2) 2 (1)
Cough 5 (2) 2 (1) 3 (1)
Asthma aggravated 7 (3) 2 (1) 1 (< 0.5)
*Only adverse events reported for ‡ 10 patients in total are included. DPI, dry-powder inhaler; pMDI, pressurised metered-dose inhaler.
Table 5 Incidence of adverse events related to treatment with b2-agonists or ICS
Adverse event
No. of patients (%)
Budesonide
pMDI (n = 217)
Budesonide/formoterol
DPI (n = 229)
Budesonide/formoterol
pMDI (n = 233)
ICS-related adverse events
Dysphonia 1 (< 0.5) 2 (1) 1 (< 0.5)
Oral candidiasis 3 (1) 5 (2) 2 (1)
b2-agonist-related adverse events
Tremor 1 (< 0.5) 2 (1) 0
Palpitation 0 6 (3) 1 (< 0.5)
Headache 4 (2) 4 (2) 4 (2)
DPI, dry-powder inhaler; ICS, inhaled corticosteroid; pMDI, pressurised metered-dose inhaler.
Figure 4 Change in AQLQ(S) following treatment with budesonide pMDI, budesonide/formoterol DPI or budesonide/
formoterol pMDI. AQLQ(S), Asthma Quality of Life Questionnaire (standardised version); DPI, dry-powder inhaler;
pMDI, pressurised metered-dose inhaler. ***p < 0.001, **p < 0.01, *p < 0.05 vs. budesonide pMDI
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with both budesonide/formoterol therapies was
within the range of that reported previously for
budesonide/formoterol DPI (2,17,28,29), thus verify-
ing the results of the present study. Furthermore, the
analysis of the secondary objective demonstrated
that, for improvements in morning PEF, budesonide/
formoterol pMDI is therapeutically equivalent to
budesonide/formoterol DPI.
Analysis of other efﬁcacy end-points relating to
lung function, asthma symptoms, disease control and
health-related quality of life supports the comparable
efﬁcacy of budesonide/formoterol pMDI with budes-
onide/formoterol DPI and the superiority of both
formulations over budesonide pMDI. The only statis-
tical differences between the two devices – which
favoured budesonide/formoterol DPI – were in the
composite end-points: symptom-free days and
asthma-control days. In both cases, differences were
driven by the additional improvement in daytime
total asthma symptom score (data not shown). Previ-
ous studies report that the degree of lung deposition
for the DPI device is approximately 2–3 times that of
the corresponding pMDI device (30–32) and hence it
is possible that this may have contributed to the sig-
niﬁcant differences in symptom-free days and
asthma-control days observed in this study. However,
there is no existing literature regarding the relative
degree of lung deposition for budesonide/formoterol
DPI or pMDI and as the degree of lung deposition
varies for different DPIs and pMDIs it cannot be
assumed that Turbuhaler DPI will deliver 2–3 times
more drug to the lungs when compared with a
pMDI (33). Instead it is more likely that any
improvements in asthma symptoms associated with
DPI are due to random variation and a much larger
study would be required to detect a clear difference
in outcome for these variables. Furthermore, as there
were no differences between the two devices in end-
points such as nighttime awakenings, 24-h total
asthma symptom scores and reliever medication use
(markers of asthma control), and in the number of
adverse events reported as asthma aggravated (an
indicator of more severe events), it is unlikely that
the difference in daytime symptom variables is clini-
cally important. Interestingly, the improvements in
lung function and symptom-related end-points with
both budesonide/formoterol therapies appeared to be
progressive, with the evidence of continuing
improvement between weeks 2 and 6 (Figures 1–3).
Conversely, but perhaps not unexpectedly, there
appeared to be little evidence of progressive improve-
ment with budesonide pMDI in this patient popula-
tion. As previously reported in comparative studies
of budesonide/formoterol DPI vs. budesonide DPI
(2,18,34,35), and as would be expected for an ICS
(1), budesonide pMDI improved asthma symptoms,
measures of asthma control and health-related qual-
ity of life, but these improvements were smaller
than those seen with the budesonide/formoterol
therapies.
In the clinical setting, choice of inhaler device is
less likely to depend on efﬁcacy and tolerability and
is more likely to be inﬂuenced by other factors, for
example cost, the patient’s ability to use the selected
device correctly and personal preference (36). DPI
devices are generally more expensive than pMDIs
and the therapeutic equivalence observed between
the delivery devices suggests that either would be
suitable for use in normal clinical practice. Besides
cost, differences in ease of use and technique
between pMDI and the DPI are likely to have a
large inﬂuence on choice of inhaler for individual
patients and clinicians. Although both devices are
relatively easy to use, each has technical limitations
which can limit effectiveness (37). In this study
patients were instructed on how to use the inhalers
correctly at visit 1. Each participating study site was
provided with a DPI/pMDI to be used with dispos-
able mouthpieces/actuators, allowing patients to
practise the inhalation technique. Furthermore,
results report that compliance (study drug use mea-
sured by self-reported diary recording of daily treat-
ment intake) was similar across all treatment
groups. Thus, it is unlikely that patients randomised
to receive the pMDI inhaler had any disadvantages
compared with those using the DPI with regard to
inhaler technique. In the clinical setting, providing
each individual with the most appropriate inhaler
has the potential to result in more effective patient
care (37).
In terms of safety, budesonide/formoterol pMDI,
budesonide/formoterol DPI and budesonide pMDI
were well tolerated, with a low overall incidence of
adverse events across the three treatment groups.
Adverse events were slightly more common in the
budesonide pMDI group – although this was not
thought to be clinically relevant – and the majority
of patients who reported aggravated asthma as an
adverse event were in this treatment group. Impor-
tantly, the tolerability proﬁles of both budesonide/
formoterol therapies were similar to that reported
previously for budesonide/formoterol DPI (29).
In conclusion, this study demonstrates that budes-
onide/formoterol, administered via the HFA pMDI
or DPI, is an effective and well-tolerated treatment
for adult and adolescent patients with asthma, with
both devices being therapeutically equivalent. The
availability of both devices will give clinicians greater
freedom to select a cost-effective therapy that suits
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clinicians themselves.
Acknowledgements
We would like to thank all the study investigators
for their exceptional work in conducting the trial.
We would also like to thank Lena Laxmyr (Astra-
Zeneca R&D, Lund, Sweden), who prepared the
study outline with great enthusiasm. In addition,
we would like to express our thanks to Mark Rich-
ardson (Adelphi Communications Ltd), who pro-
vided medical writing support on behalf of
AstraZeneca. This study was funded by AstraZeneca
R&D, Lund, Sweden.
References
1 National Institutes for Health. Global Initiative for Asthma. Global
Strategy for Asthma Management and Prevention. GINA Workshop
Report. Bethesda, MD: National Institutes for Health, NIH Publica-
tion No. 02-3659, 1995 (updated 2004).
2 Buhl R, Creemers JP, Vondra V et al. Once-daily budesonide/for-
moterol in a single inhaler in adults with moderate persistent
asthma. Respir Med 2003; 97: 323–30.
3 Stallberg B, Olsson P, Jorgensen LA et al. Budesonide/formoterol
adjustable maintenance dosing reduces asthma exacerbations versus
ﬁxed dosing. Int J Clin Pract 2003; 57: 656–61.
4 Fitzgerald JM, Sears MR, Boulet LP et al. Adjustable maintenance
dosing with budesonide/formoterol reduces asthma exacerbations
compared with traditional ﬁxed dosing: a ﬁve-month multicentre
Canadian study. Can Respir J 2003; 10: 427–34.
5 O’Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol
combination therapy as both maintenance and reliever medication
in asthma. Am J Respir Crit Care Med 2005; 171: 129–36.
6 Scicchitano R, Aalbers R, Ukena D et al. Efﬁcacy and safety of bu-
desonide/formoterol single inhaler therapy versus a higher dose of
budesonide in moderate to severe asthma. Curr Med Res Opin
2004; 20: 1403–18.
7 Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in
a single inhaler for maintenance and relief in mild-to-moderate
asthma: a randomized, double-blind trial. Chest 2006; 129: 246–56.
8 Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler)
showed as rapid an onset of action as salbutamol given by a
pMDI. Respir Med 2000; 94: 607–11.
9 Palmqvist M, Persson G, Lazer L et al. Inhaled dry-powder
formoterol and salmeterol in asthmatic patients: onset of
action, duration of effect and potency. Eur Respir J 1997; 10:
2484–9.
10 Miller-Larsson A, Mattsson H, Hjertberg E et al. Reversible fatty
acid conjugation of budesonide. Novel mechanism for prolonged
retention of topically applied steroid in airway tissue. Drug Metab
Dispos 1998; 26: 623–30.
11 Miller-Larsson A, Jansson P, Runstrom A et al. Prolonged airway
activity and improved selectivity of budesonide possibly due to
esteriﬁcation. Am J Respir Crit Care Med 2000; 162: 1455–61.
12 Thorsson L, Thunnisen FBJM, Korn S et al. Formation of fatty
acid conjugates of budesonide in human lung tissue in vivo
[abstract]. Am J Respir Crit Care Med 1998; 157 (Suppl. 3): A404.
13 Balanag VM, Yunus F, Yang PC et al. Efﬁcacy and safety of budes-
onide/formoterol compared with salbutamol in the treatment of
acute asthma. Pulm Pharmacol Ther 2006; 19: 139–47.
14 Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered
by Turbuhaler is effective in a dose-dependent fashion when used
in the treatment of adult patients with chronic asthma. J Allergy
Clin Immunol 1998; 101: 457–63.
15 Foresi A, Morelli MC, Catena E. Low-dose budesonide with the
addition of an increased dose during exacerbations is effective in
long-term asthma control. On behalf of the Italian Study Group.
Chest 2000; 117: 440–6.
16 Palmqvist M, Ibsen T, Mellen A et al. Comparison of the relative
efﬁcacy of formoterol and salmeterol in asthmatic patients. Am
J Respir Crit Care Med 1999; 160: 244–9.
17 Aalbers R, Backer V, Kava TT et al. Adjustable maintenance dosing
with budesonide/formoterol compared with ﬁxed-dose salmeterol/
ﬂuticasone in moderate to severe asthma. Curr Med Res Opin
2004; 20: 225–40.
18 Pohl WR, Vetter N, Zwick H et al. Adjustable maintenance dosing
with budesonide/formoterol or budesonide: double-blind study.
Respir Med 2006; 100: 551–60.
19 Vogelmeier C, D’Urzo A, Pauwels R et al. Budesonide/formoterol
maintenance and reliever therapy: an effective asthma treatment
option? Eur Respir J 2005; 26: 819–28.
20 Ross DL, Gabrio BJ. Advances in metered dose inhaler technology
with the development of a chloroﬂuorocarbon-free drug delivery
system. J Aerosol Med 1999; 12: 151–60.
21 Leach CL. The CFC to HFA transition and its impact on pulmo-
nary drug development. Respir Care 2005; 50: 1201–8.
22 American Thoracic Society. Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease (COPD) and
asthma. Am Rev Respir Dis 1987; 136: 225–44.
23 Juniper EF, Buist AS, Cox FM et al. Validation of a standardized
version of the Asthma Quality of Life Questionnaire. Chest 1999;
115: 1265–70.
24 Polgar G, Promadhat V. Maximal air ﬂow rates. In: Polgar G, ed.
Pulmonary Function Testing in Children: Techniques and Standards.
Philadelphia, PA: W. B. Saunders Company, 1971: 170–95.
25 Quanjer PH, Tammeling GJ, Cotes JE et al. Lung volumes and
forced ventilatory ﬂows. Report Working Party Standardization of
Lung Function Tests, European Community for Steel and Coal.
Ofﬁcial Statement of the European Respiratory Society. Eur Respir
J Suppl 1993; 16: 5–40.
26 Juniper EF, Guyatt GH, Willan A et al. Determining a minimal
important change in a disease-speciﬁc Quality of Life Question-
naire. J Clin Epidemiol 1994; 47: 81–7.
27 Bateman ED, Silins V, Bogolubov M. Clinical equivalence of
salmeterol/ﬂuticasone propionate in combination (50/100 microg
twice daily) when administered via a chloroﬂuorocarbon-free
metered dose inhaler or dry powder inhaler to patients with mild-
to-moderate asthma. Respir Med 2001; 95: 136–46.
28 Bateman ED, Bantje TA, Joao Gomes M et al. Combination ther-
apy with single inhaler budesonide/formoterol compared with high
dose of ﬂuticasone propionate alone in patients with moderate
persistent asthma. Am J Respir Med 2003; 2: 275–81.
29 Goldsmith DR, Keating GM. Budesonide/formoterol: a review of
its use in asthma. Drugs 2004; 64: 1597–618.
30 Borgstrom L, Derom E, Stahl E et al. The inhalation device inﬂu-
ences lung deposition and bronchodilating effect of terbutaline.
Am J Respir Crit Care Med 1996; 153: 1636–40.
31 Thorsson L, Edsbacker S, Conradson TB. Lung deposition of
budesonide from Turbuhaler is twice that from a pressurized
metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839–
44.
32 Selroos O, Borgstrom L, Ingelf J. Performance of Turbuhal-
er((R)) in patients with acute airway obstruction and COPD,
and in children with asthma : understanding the clinical impor-
tance of adequate peak inspiratory ﬂow, high lung deposition,
and low in vivo dose variability. Treat Respir Med 2006; 5:
305–15.
33 Thorsson L, Edsbacker S, Kallen A et al. Pharmacokinetics and
systemic activity of ﬂuticasone via Diskus and pMDI, and of
budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529–
38.
1882 Therapeutic equivalence of bud/form pMDI and DPI
ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, November 2007, 61, 11, 1874–188334 Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control
with budesonide/formoterol in a single inhaler, compared with
budesonide alone. Eur Resp J 2001; 18: 262–8.
35 Tal A, Simon G, Vermeulen JH et al. Budesonide/formoterol in a
single inhaler versus inhaled corticosteriods alone in the treatment
of asthma. Pediatr Pulmonol 2002; 34: 342–50.
36 Dolovich MB, Ahrens RC, Hess DR et al. Device selection and out-
comes of aerosol therapy: Evidence-based guidelines: American
College of Chest Physicians/American College of Asthma, Allergy,
and Immunology. Chest 2005; 127: 335–71.
37 Fink JB, Rubin BK. Problems with inhaler use: a call for improved
clinician and patient education. Respir Care 2005; 50: 1360–74.
Paper received April 2007, accepted August 2007
Therapeutic equivalence of bud/form pMDI and DPI 1883
ª 2007 The Authors
Journal compilation ª 2007 Blackwell Publishing Ltd Int J Clin Pract, November 2007, 61, 11, 1874–1883